509 related articles for article (PubMed ID: 7951103)
1. Quantitative studies on graft-versus-leukemia after allogeneic bone marrow transplantation in rat models for acute myelocytic and lymphocytic leukemia.
Kloosterman TC; Tielemans MJ; Martens AC; van Bekkum DW; Hagenbeek A
Bone Marrow Transplant; 1994 Jul; 14(1):15-22. PubMed ID: 7951103
[TBL] [Abstract][Full Text] [Related]
2. Graft-versus-leukemia in rat MHC-mismatched bone marrow transplantation is merely an allogeneic effect.
Kloosterman TC; Martens AC; van Bekkum DW; Hagenbeek A
Bone Marrow Transplant; 1995 Apr; 15(4):583-90. PubMed ID: 7655385
[TBL] [Abstract][Full Text] [Related]
3. Interleukin-2 therapy after allogeneic bone marrow transplantation for acute myelocytic leukemia: studies in a relevant rat model for AML.
Kloosterman TC; Martens AC; Osterwalder B; Hagenbeek A
Bone Marrow Transplant; 1994 Dec; 14(6):965-73. PubMed ID: 7711675
[TBL] [Abstract][Full Text] [Related]
4. Influence of ultraviolet-B irradiation on engraftment, graft-versus-host disease and graft-versus-leukemia effect in a rat model for allogeneic bone marrow transplantation.
Gowing H; Braakman E; Hagenbeek A; Lawler M; McCann SR; Pamphilon DH; Martens AC
Bone Marrow Transplant; 1998 Apr; 21(8):801-7. PubMed ID: 9603404
[TBL] [Abstract][Full Text] [Related]
5. A second prophylactic MHC-mismatched bone marrow transplantation protects against rat acute myeloid leukemia (BNML) without lethal graft-versus-host disease.
Nestvold JM; Omdal BK; Dai KZ; Martens A; Benestad HB; Vaage JT; Rolstad B
Transplantation; 2008 Jan; 85(1):102-11. PubMed ID: 18192919
[TBL] [Abstract][Full Text] [Related]
6. Eradication of residual disease by administration of leukemia-specific T cells after experimental allogeneic bone marrow transplantation.
Zeis M; Uharek L; Glass B; Vosskötter W; Dreger P; Schmitz N; Steinmann J
Exp Hematol; 1998 Oct; 26(11):1068-73. PubMed ID: 9766447
[TBL] [Abstract][Full Text] [Related]
7. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
8. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
[TBL] [Abstract][Full Text] [Related]
9. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.
Johnson BD; Drobyski WR; Truitt RL
Bone Marrow Transplant; 1993 Apr; 11(4):329-36. PubMed ID: 8485480
[TBL] [Abstract][Full Text] [Related]
10. The graft-versus-leukemia (GVL) phenomenon: is GVL separable from GVHD?
Slavin S; Ackerstein A; Naparstek E; Or R; Weiss L
Bone Marrow Transplant; 1990 Sep; 6(3):155-61. PubMed ID: 2252954
[TBL] [Abstract][Full Text] [Related]
11. Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
Sykes M; Bukhari Z; Sachs DH
Bone Marrow Transplant; 1989 Sep; 4(5):465-74. PubMed ID: 2790325
[TBL] [Abstract][Full Text] [Related]
12. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2.
Weiss L; Lubin I; Factorowich I; Lapidot Z; Reich S; Reisner Y; Slavin S
J Immunol; 1994 Sep; 153(6):2562-7. PubMed ID: 8077666
[TBL] [Abstract][Full Text] [Related]
13. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic bone marrow transplantation for leukemia with marrow grafts treated by counterflow centrifugation.
De Witte T; Schattenberg A; Preijers F; Raymakers R; Muus P; Wessels J
Bone Marrow Transplant; 1993; 12 Suppl 3():S2-6. PubMed ID: 8124252
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapeutic aspects of allogeneic peripheral progenitor cells.
Glass B; Uharek L; Hartung G; Zeis M; Steinmann J; Dreger P; Krönke M; Schmitz N
Bone Marrow Transplant; 1998 Jun; 21 Suppl 3():S3-8. PubMed ID: 9712483
[TBL] [Abstract][Full Text] [Related]
17. CD28/B7 interactions are required for sustaining the graft-versus-leukemia effect of delayed post-bone marrow transplantation splenocyte infusion in murine recipients of myeloid or lymphoid leukemia cells.
Blazar BR; Taylor PA; Boyer MW; Panoskaltsis-Mortari A; Allison JP; Vallera DA
J Immunol; 1997 Oct; 159(7):3460-73. PubMed ID: 9317145
[TBL] [Abstract][Full Text] [Related]
18. Allospecific CD8+ Tc1 and Tc2 populations in graft-versus-leukemia effect and graft-versus-host disease.
Fowler DH; Breglio J; Nagel G; Eckhaus MA; Gress RE
J Immunol; 1996 Dec; 157(11):4811-21. PubMed ID: 8943383
[TBL] [Abstract][Full Text] [Related]
19. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation.
Li JM; Waller EK
Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532
[TBL] [Abstract][Full Text] [Related]
20. The influence of graft-versus-host reactivity, lymphocyte depletion, and cell dose on allogeneic bone marrow engraftment.
Glass B; Uharek L; Gaska T; Gassmann W; Löffler H; Müller-Ruchholtz W
Bone Marrow Transplant; 1993; 12 Suppl 3():S41-7. PubMed ID: 8124257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
